冠心病充血性心力衰竭患者心肌纤维化水平及缬沙坦对其的影响

目的研究冠心病充血性心力衰竭患者心肌纤维化水平及缬沙坦对其的影响。方法选择冠心病充血性心力衰竭患者50例为试验组,又将该组患者随机分为缬沙坦组和安慰剂组;另入选正常对照组30例。所有受检者于开始治疗前及试验组患者用药6个月结束后检测血清Ⅲ型前胶原氨基端肽(PⅢP)和透明质酸(HA)浓度。结果治疗前,安慰剂组和缬沙坦组PⅢP和HA水平两组间差异无显著性(P>0.05),而同正常对照组相比均明显增高(P<0.05);治疗后,缬沙坦组PⅢP和HA水平较安慰剂组显著降低(P<0.05),且同治疗前相比两组PⅢP和HA水平均有减低,但仅缬沙坦组差异有显著性(P<0.05)。结论冠心病充血性心力衰竭患者心肌纤维化水平明显高于健康人,经缬沙坦治疗可改善心肌纤维化程度。

Change of myocardial fibrosis in coronary heart disease with congestive myocardial failure and influence of valsartan therapy

Objective To investigate the Change of myocardial fibrosis in coronary heart disease with congestive myocardial failure and influence of valsartan therapy. Methods A total of 50 patients in coronary heart disease with congestive myocardial failure were selected (trail group) and were selected randomly to valsartan group and placebo group. Normal control group consist of 30 patients. Procollagen type Ⅲ aminoterminal peptide(PⅢP) and hyaluronic acid (HA) of all patients were analyzed at baseline, 6 months after given valsartan and placebo in trail patients. Results The levels of PⅢP and HA between valsartan group and placebo group were no difference at baseline (P>0.05); but all significantly higer than normal control group(P<0.05). After given valsartan and placebo,The levels of PⅢP and HA in valsartan group was lower than placebo group (P<0.05),and significantly lower than that at baseline (P<0.05). Conclusion The levels of PⅢP and HA are higer in patients with coronary heart disease complicating congestive heart failure,depress if given valsartan.